Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN.
Jacob Pontoppidan ThyssenJonathan Ian SilverbergJ RuanoAndrew BlauveltW GubelinEric L SimpsonS WeidingerH ValdezK K TerryP BiswasE GülerC FeeneyPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Maintenance of response using reduced-dose abrocitinib 100 mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200 mg induction treatment.
Keyphrases